However, the study found compared to the placebo group:

• Participants treated with semaglutide exhibited a broad pattern of slower biological aging across epigenetic clocks linked to inflammation and blood, brain, heart, kidney, liver and metabolic health.

• The drug slowed the pace of biological aging by 9 %, as measured by the DunedinPACE epigenetic clock.

• The drug significantly slowed biological processes associated with the risk of all‑cause mortality and age-related disease, as measured by the PCGrimAgeepigenetic clock.

It's just that the study focused on people with a particular condition so it takes more studies to know if it affects the general population similarly.